Abstracts tagged "research methods and treatment"

Abstract Number: 1714 • 2018 ACR/ARHP Annual Meeting
Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, R. Paola Daly¹, Leslie Hanrahan², Annick Anderson³, Kathleen Arntsen⁴, Sang-Cheol Bae⁵, Ian N. Bruce⁶, Karen Costenbader⁷, Thomas Dörner⁸, Amy H. Kao⁹, Susan Manzi¹⁰, Eric Morand¹¹, Sandra Raymond¹, Brad H. Rovin¹², Laura E. Schanberg¹³, Victoria P. Werth¹⁴, Joan Von Feldt¹⁵ and Kenneth Getz³, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Washington DC, DC, ³Tufts Center for the Study of Drug Development, Boston, MA, ⁴Lupus and Allied Diseases, Inc., Verona, NY, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ⁹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹⁰Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ¹¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹²Ohio State University Medical Center, Columbus, OH, ¹³Duke University Medical Center, Durham, NC, ¹⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁵GlaxoSmithKline, Philadelphia, PA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus initiative seeking to identify and prioritize top barriers in lupus impacting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].